Health Care Professionals


Santhera is passionate about developing new treatments for patients with rare diseases. Our focus is on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options.

Our earlier-stage pipeline

In February 2018, Santhera in-licensed from Polyphor lonodelestat (POL6014), a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other lung diseases. The pipeline also includes omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies.